| 332 | 1 | 27 |
| 下载次数 | 被引频次 | 阅读次数 |
大肠癌已经成为全世界第三大常见癌症，癌症相关的第二大死因。早期筛查可降低CRC的发生率和死亡率。随着粪便免疫化学试验的发展，FIT已经成为全世界大肠癌高危人群筛查大肠癌的重要手段。本文就FIT筛查CRC的研究进展进行阐述。
Abstract：Colorectal cancer has become the third most common cancer in the world and the second leading cause of death related to cancer.Early screening of CRC can reduce its incidence rate and mortality.With the development of fecal immunochemical test,FIT has been an important tool for screening CRC patients in high-risk groups worldwide.In this paper,we describe the research progress of FIT screening for CRC.
1 Siegel RL,Miller KD,Goding Sauer A,et al.Colorectal cancer statistics,2020[J].CA Cancer J Clin,2020,70(3):145-164.
2 Benard F,B arkun AN,Martel M,et al.Systematic review of colorectal cancer screening guidelines for average-risk adults:Summarizing the current global recommendations[J].World J Gastroenterol,2018,24(1):124-138.
3 Choe L,Lau J,Yip LT,et al.Gastroscopy after positive screening for faecal immunochemical tests and colonoscopy:A systematic review[J].PLoS One,2023,18(2):e0281557.
4 Bailey JA,Ibrahim H,Bunce J,et al.Quantitative FIT stratification is superior to NICE referral criteria NG12 in a high-risk colorectal cancer population[J].Tech Coloproctol,2021,25(10):1151-1154.
5 D'Souza N,Georgiou Delisle T,Chen M,et al.Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway:A diagnostic accuracy study[J].Gut,2021,70(6):1130-1138.
6王艳丽,雷微,王川,等.重庆地区平均风险人群大肠腺瘤检出情况及危险因素分析[J].检验医学与临床,2018,15(20):3033-3036,3040.
7 Dekker F,Tanis PJ,Vleugels JLA,et al.Colorectal cancer[J].Lancet,2019,394(10207):1467-1480.
8 Simon K.Colorectal cancer development and advances in screening[J].Clin Interv Aging,2016,11:967-976.
9 Bretthauer M,Loberg M,Wieszczy M.Effectiveness of colonoscopy for colorectal cancer screening in reducing cancer-related mortality:Interpreting the results from two ongoing randomized trials[J].JCOM,2022,29(6):196-205.
10 Larsen MB,Njor S,Ingeholm P,et al.Effectiveness of colorectal cancer screening in detecting earlier-stage disease-a nationwide cohort study in denmark[J].Gastroenterology,2018,155(1):99-106.
11 Chiu HM,Jen GHH,Wang YW,et al.Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers[J].Gut,2021,70(12):2321-2329.
12何慧,吴伟晴,廖淑萍,彭锐,张琼华,赵莉.定量便潜血试验在结直肠癌伺机性筛查中的效果评估[J].中华健康管理学杂志,2021,15(3):263-268.
13 Navarro M,Nicolas A,Ferrandez A,et al.Colorectal cancer population screening programs worldwide in2016:An update[J].World J Gastroenterol,2017,23(20):3632-3642.
14孟凡一,周如琛,李延青.粪便免疫化学试验在结直肠癌早期诊断中应用的研究进展[J].老年医学研究,2021,2(6):40-45.
15国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化病学分会幽门螺杆菌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华健康管理学杂志,2019,13(4):285-291.
16 Wang L,Chen H,Zhu Y,et al.One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening:A cross-sectional study in China[J].BMJ Open,2022,12(5):e059754.
17张桔红,张凌玲,林玮.金标法测便类潜血中的后带现象[J].实用医技杂志,2004,(4):402-403.
18董华,王定彬,华婧,等.2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J].实用肿瘤学杂志,2021,35(4):344-350.
19房静远,李延青,陈萦晅,等.中国大肠肿瘤综合预防共识意见(2021年,上海)[J].胃肠病学,2021,26(5):279-311.
20 Zeraatkar D,Han MA,Guyatt GH,et al.Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes:A systematic review and meta-analysis of cohort studies[J].Ann Intern Med,2019,171(10):703-710.
21王淑辉,刘丽波,孔学哲.河北省承德地区大肠息肉发生的相关因素调查研究[J].安徽药,2022,26(1):35-39.
22 Rawla P,Sunkara T,Barsouk A.Epidemiology of colorectal cancer:Incidence,mortality,survival,and risk factors[J].Prz Gastroenterol,2019,14(2):89-103.
23崔小娇,戴海辉,王森.2013年上海市青浦区白鹤镇社区卫生服务中心大肠癌筛查流行病学特征分析[J]智慧健康,2020,6(13):39-41.
24 Abdelnaby HB,Abuhussein A A,Fouad AM,et al.Histopathological and epidemiological findings of colonoscopy screening in a population with an average risk of colorectal cancer in Kuwait[J].Saudi J Gastroenterol,2021,27(3):158-165.
25 Robertson DJ,Ladabaum U.Opportunities and challenges in moving from current guidelines to personalized colorectal cancer screening[J].Gastroenterology,2019,156(4):904-917.
26王锡山.中美大肠癌流行病学特征及防诊治策略的对比分析[J/CD].中华大肠疾病电子杂志,2017,6(6):447-453.
27 Wu D,Zhou G,Jin P,et al.Detection of colorectal cancer using a simplified SEPT9 Gene methylation assay is a reliable method for opportunistic screening[J].J Mol Diagn,2016,18(4):535-545.
28张春燕,于正麟,王蓓丽,等.血浆Septin9基因甲基化检测性能评价及对大肠癌患者的筛查价值[J].临床检验杂志,2019,37(2):152-155.
29郭颖,裴冬梅,张耐思.粪便免疫化学检测结果与体重、血脂等的相关性分析[J].现代肿瘤医学,2021,29(6):1017-1020.
30 Akram A,Juang D,Bustamante R,et al.Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting[J].Clin Gastroenterol Hepatol,2017,15(8):1265-1270.el.
31蔡金平,刘琼,李琴.免疫法与化学法粪便隐血试验在大肠癌早期筛查中的应用比较[J].中国当代医药,2021,28(20):183-186.
32 Lee JK,Liles EG,Bent S,et al.Accuracy of fecal immunochemical tests for colorectal cancer:Systematic review and meta-analysis[J].Ann Intern Med,2014,160(3):171.
33 Tinmouth J,Lansdorp-Vogelaar I,Allison JE.Faecal immunochemical tests versus guaiac faecal occult blood tests:What clinicians and colorectal cancer screening programme organisers need to know[J].Gut,2015,64(8):1327-1337.
34 Selby K,Levine EH,Doan C,et al.Effect of sex,age,and positivity threshold on fecal immunochemical test accuracy:A systematic review and meta-analysis[J].Gastroenterology,2019,157(6):1494-1505.
35 Mikael C,Manon PC,Marie M,et al.Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population[J].Clin Res Hepatol Gastroenterol,2023:102093.
36 Berry E,Miller S,Koch M,et al.Lower abnormal fecal immunochemical test cut-off values improve detection of colorectal cancer in system-level screens[J].Clin Gastroenterol Hepatol,2020,18(3):647-653.
37 Cross AJ,Wooldrage K,Robbins EC,et al.Faecal immunochemical tests(FIT)versus colonoscopy for surveillance after screening and polypectomy:A diagnostic accuracy and cost-effectiveness study[J].Gut,2019,68(9):1642-1652.
38 Brenner DR,Heer E,Sutherland RL,et al.National trends in colorectal cancer incidence among older and younger adults in Canada[J].JAMA Netw Open,2019,2(7):e198090.
39 Nwankwo EC,Lines J,Trehan S,et al.Improving adenoma detection rates:The role of the fecal immunochemical test[J].Cureus,2021,13(4):e14382.
40 Zhao S,Wang S,Pan P,et al.FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population:A nationwide multicenter prospective study[J].J Hematol Oncol,2022,15(1):1-6.
41 Khasawneh F,Osborne T,Danaher P,et al.Faecal immunochemical testing reduces demand and improves yield of Leicester's 2-week pathway for change in bowel habit[J].Colorectal Dis,2023,25(4):640-646.
42 Daly JM,Xu Y,Levy BT.Which fecal immunochemical test should I choose?[J].J Prim Care Community Health,2017,8(4):264-277.
43 Gerrard AD,Maeda Y,Miller J,et al.Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer[J].Br J Surg,2023,110(4):471-480.
44 Clark GRC,Steele RJC,Fraser CG.Strategies to minimise the current disadvantages experienced by women in faecal immunochemical test-based colorectal cancer screening[J].Clin Chem Lab Med,2022,60(10):1496-1505.
45 Brenner H,Qian J,Werner S.Variation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age:Results from a large screening cohort[J].Clin Epidemiol,2018,10:381.
46 Breekveldt ECH,Toes-Zoutendijk E,van de Schootbrugge-Vandermeer HJ,et al.Factors associated with interval colorectal cancer after negative FIT:Results of two screening rounds in the Dutch FIT-based CRCscreening program[J].Int J Cancer,2023,152(8):1536-1546.
47 Heer E,Ruan Y,Pader J,et al.Performance of the fecal immunochemical test for colorectal cancer and advanced neoplasia in individuals under age 50[J].Prev Med Rep,2023,32:102124.
48 George AT,Aggarwal S,Dharmavaram S,et al.Faecal occult blood testing screening for colorectal cancer and'missed'interval cancers:Are we ignoring the elephant in the room?Results of a multicentre study[J].Colorectal Dis,2017,19(5):0108-0114.
49 Burón A,MaciàF,Andreu M,et al.Population-based colorectal cancer screening:Interval cancers and relationship with the quantitative faecal immunological for hemoglobin[J].Med Clin(Barc),2019,152(8):303-306.
50 Veerdonk W,Hoeck S,Peeters M,et al.Occurrence and characteristics of faecal immunochemical screen-detected cancers vs.non-screen-detected cancers:Results from a Flemish colorectal cancer screening programme[J].United European Gastroenterol J,2020,8(2):185-194.
51 Portillo I,Arana-Arri E,Idigoras I,et al.Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country(Spain)[J].World J Gastroenterol,2017,23(15):2731-2742.
52 Hasegawa R,Yashima K,Ikebuchi Y,et al.Characteristics of advanced colorectal cancer detected by fecal immunochemical test screening in participants with a negative result the previous year[J].Yonago Acta Med,2020,63(1):63-69.
53 Lincoln A,Benton S,Piggott C,et al.Exploring the utility and acceptability of faecal immunochemical testing(FIT)as a novel intervention for the improvement of colorectal Cancer(CRC)surveillance in individuals with lynch syndrome(FIT for lynch study):A single-arm,prospective,multi-centre,non-randomised study[J].BMC Cancer,2022,22(1):1-11.
54 Ribe SG,Botteri E,Loberg M,et al.Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results:A natural experiment[J].Int J Cancer,2023,152(7):1414-1424.
55 Clark GR,Fraser CG,Strachan JA,et al.Comparisonwith first round findings of faecal haemoglobin concentrations and clinical outcomes in the second round of a biennial faecal immunochemical test based colorectal cancer screening programme[J].J Med Screen,2022,29(4):249-254.
56 Ding H,Lin J,Xu Z,et al.A global evaluation of the performance indicators of colorectal cancer screening with fecal immunochemical tests and colonoscopy:A systematic review and meta-analysis[J].Cancers,2022,14(4):1073.
57马铭骏,李延青.探索中国结直肠癌筛查新模式[J].中国医刊,2021,56(12):1281-1284.
58 Selby K,Baumgartner C,Levin TR,et al.Interventions to improve follow-up of positive results on fecal blood tests:A systematic review[J].Ann Intern Med,2017,167(8):565-575.
59黎琼,王伟,郑秀丽,等.上海市闵行区颛桥镇社区居民结直肠癌筛查结果和结肠镜依从性探讨[J].胃肠病学,2021,26(8):477-480.
60 Wu W,Chen X,Fu C,et al.Risk scoring systems for predicting the presence of colorectal neoplasia by fecal immunochemical test results in Chinese population[J].Clin Transl Gastroenterol,2022,13(10):e00525.
61汤军,欧俐苹,陈玲,等.4种血清肿瘤标志物及粪便隐血的联合检测在Dukes B期结肠癌诊断中的应用[J].重庆医学,2017,46(22):3073-3076
62 Niedermaier T,Balavarca Y,Brenner H.Stage-specific sensitivity of fecal immunochemical tests for detecting colorectal cancer:Systematic review and meta-analysis[J].Am J Gastroenterol,2020,115(1):56-69.
63申艺,向德兵,孙贵银.多靶点粪便FIT-DNA检测对中国人群结直肠癌筛查价值的meta分析[J/OL].重庆医学:1-8.
64肠癌居家筛查助力癌症防治关口前移.光明网[引用日期2021-10-26].
65中国结直肠癌筛查与早诊早治指南(2020,北京).中国肿瘤杂志公众号.
66 Li YL,Guan X,Don LZ,et al.The clinical value of multi-target stool fecal immunochemical test-DNA in early screening and diagnosis for colorectal cancer[J].Zhonghua Yi Xue Za Zhi,2022,102(33):2607-2613.
基本信息:
DOI：10.13210/j.cnki.jhmu.20230327.003
中图分类号:R735.34
引用信息:
[1]曾凡,陈晨,黄士美,等.粪便免疫化学试验筛查大肠癌的研究进展[J].海南医学院学报,2023,29(22):1748-1754.DOI:10.13210/j.cnki.jhmu.20230327.003.
基金信息:
海南省临床医学中心建设项目资助（2021818）; 海南省院士团队创新中心建设项目资助（2022136）; 海南省院士创新平台科研项目资金资助（00817378）; 海南省卫生健康行业科研项目资助（22A200078）; 海南省研究生创新科研课题（Qhyb2022-133）~~
2023-03-28
2023-03-28
2023-03-28